Timolol

Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.

Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.

Timolol Maleate (0.5% w/v) is a non-selective beta-1 and beta-2 adrenergic receptor antagonist on the WHO Model List of Essential Medicines. It blocks beta-adrenergic receptors on non-pigmented ciliary epithelial cells, inhibiting cyclic AMP synthesis and reducing aqueous humor secretion by 30-50% without altering pupillary size or accommodation. Indicated for lowering elevated intraocular pressure in patients with chronic open-angle glaucoma and ocular hypertension.

Bimatoprost (0.01%, 0.03% w/v, alone or with Timolol 0.5%) is a synthetic prostamide (cyclopentane amide) ocular hypotensive agent on the WHO Model List of Essential Medicines. It structurally mimics endogenous prostamides, binding to unique prostamide receptors to simultaneously increase both trabecular meshwork and uveoscleral aqueous humor outflow, achieving powerful intraocular pressure reduction. Indicated for the reduction of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Travoprost (0.004% w/v, alone or with Timolol 0.5%) is a synthetic prostaglandin F2-alpha analogue and full selective FP prostanoid receptor agonist on the WHO Model List of Essential Medicines. It significantly enhances uveoscleral aqueous outflow. Indicated for lowering intraocular pressure in open-angle glaucoma and ocular hypertension.

Latanoprost and Timolol Maleate ophthalmic solution is a fixed-combination ocular hypotensive therapy. Latanoprost (0.005%), a prostaglandin F2-alpha analogue, increases uveoscleral outflow of aqueous humor, while timolol (0.5%), a non-selective beta-adrenergic blocker, reduces aqueous humor production in the ciliary processes. Combining these two complementary mechanisms achieves substantial, sustained intraocular pressure (IOP) reduction. Indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy.